Result of General Meeting & TVR

Creo Medical Group PLC

18 October 2024

 

THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

LEI: 213800H188ZDCWWXFA21

18 October 2024

Creo Medical Group plc

("Creo" or the "Company")

Result of General Meeting

and Total Voting Rights

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy for cancer and pre-cancer patients, is pleased to announce that at its General Meeting held today all of the resolutions, as set out in the Circular dated 1 October 2024, were duly passed.

The voting results will be made available on the Company's website shortly at:

https://creomedical.com/en/investors/reports-and-presentations

Application has been made for a total of 50,369,109 New Ordinary Shares, to be issued pursuant to the Placing and Retail Offer, to be admitted to trading on AIM. It is expected that Admission and dealings in the 50,369,109 New Ordinary Shares will commence at 8.00 a.m. on 21 October 2024. Following Admission, the Enlarged Share Capital of the Company will consist of 412,148,979 Ordinary Shares. Therefore, the total number of voting rights in the Company is 412,148,979 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Company, or there is a change to their interest in the Company.

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 1 October 2024, copies of which are available on the Company's website www.creomedical.com/investors. The same definitions apply throughout this announcement as are applied in the Circular.

For further information please contact: 

Creo Medical Group plc	www.creomedical.com
Richard Craven, Company Secretary	Via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser, Joint Bookrunner and Joint Broker)	[phone]
Stephen Keys / Camilla Hume / George Lawson (NOMAD)
Michael Johnson (Sales)
Deutsche Numis (Joint Bookrunner and Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown William Baunton (ECM)	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END